Potential of Mirabegron and its Extended-release Formulations for the Treatment of Overactive Bladder Syndrome

Author(s): Pankaj Mandpe, Bala Prabhakar, Pravin Shende*

Journal Name: Current Drug Metabolism

Volume 21 , Issue 2 , 2020


Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Abstract:

Background: Overactive bladder syndrome is a broadly occurring urological disorder with a distressing impact on the quality of life. The commonly used antimuscarinic drugs show poor patient compliance because of unsatisfactory potency, tolerability and high occurrence of adverse effects such as dry mouth, blurred vision, constipation, dizziness etc. Mirabegron is the first approved β3-adrenoreceptor agonist, used as mono or in combination therapies for overactive bladder syndrome.

Objective: The present review provides an insight into the mechanism, pharmacokinetics, toxicokinetics, clinical trials and the development of various conventional and modified-release dosage forms of mirabegron for the treatment of overactive bladder syndrome.

Results: The clinical trials of phase II and phase III of mirabegron demonstrated symptomatic relief from the overactive bladder without disturbing the micturition cycle. To date, mirabegron showed promising results for safety, tolerability and efficacy in patients with overactive bladder syndrome. The modified-release tablet dosage form of mirabegron appear to be a proficient and suitable replacement for antimuscarinics and revealed the tremendous potential to overcome the adverse effects of conventional antimuscarinic drugs like Oxybutyline chloride ER, Detrol LA, VESIcare, etc.

Conclusion: Mirabegron shows a distinct mode of action, i.e., targeting β3-adrenoreceptors and improving bladder storage without altering void contractions. The limited side effects, high safety, efficacy and tolerability of mirabegron present an adequate substitute to antimuscarinics. However, long-term analysis and clinical studies are prerequisites for assessing the safety, tolerability and efficacy profile of mirabegron.

Keywords: Mirabegron, antimuscarinics, overactive bladder, modified-release, mechanism, pharmacokinetic.

[1]
Lee, R.T.; Bamberger, M.; Ellsworth, P. Impact of mirabegron extended-release on the treatment of overactive bladder with urge urinary incontinence, urgency, and frequency. Res. Rep. Urol., 2013, 5, 147-157.
[PMID: 24400246]
[2]
Sacco, E.; Bientinesi, R. Mirabegron: a review of recent data and its prospects in the management of overactive bladder. Ther. Adv. Urol., 2012, 4(6), 315-324.
[http://dx.doi.org/10.1177/1756287212457114] [PMID: 23205058]
[3]
Deeks, E.D. Mirabegron: A review in overactive bladder syndrome. Drugs, 2018, 78(8), 833-844.
[http://dx.doi.org/10.1007/s40265-018-0924-4] [PMID: 29869204]
[4]
Aballéa, S.; Maman, K.; Thokagevistk, K.; Nazir, J.; Odeyemi, I.A.; Hakimi, Z.; Garnham, A.; Toumi, M. Cost effectiveness of mirabegron compared with tolterodine extended release for the treatment of adults with overactive bladder in the United Kingdom. Clin. Drug Investig., 2015, 35(2), 83-93.
[http://dx.doi.org/10.1007/s40261-014-0240-z] [PMID: 25491433]
[5]
Sanford, M. Mirabegron: a review of its use in patients with overactive bladder syndrome. Drugs, 2013, 73(11), 1213-1225.
[http://dx.doi.org/10.1007/s40265-013-0086-3] [PMID: 23818156]
[6]
Imran, M.; Najmi, A.K.; Tabrez, S. Mirabegron for overactive bladder: a novel, first-in-class β3-agonist therapy. Urol. J., 2013, 10(3), 935-940.
[PMID: 24078498]
[7]
Patel, D.A.; Patel, D.J. Physicochemical characterization and in-vitro dissolution enhancement of mirabegron using solid dispersion method. World J. Pharm. Pharm. Sci., 2018, 7(5), 973-991.
[8]
Peter, F.; Ken, D. Extended-release delivery technology. Drug Del. Form., 2006, 7, 79-86.
[9]
Shah, M.S.J.; Shah, P.B.; Patel, M.S.; Patel, M.R. A review on extended-release drug delivery system and multiparticulate system. World. J. Pharm. Res., 2015, 4990, 724-747.
[10]
Augsburger, L.L.; Hoag, S.W. Pharmaceutical Dosage Forms: Tablets, 3rd ed; Taylor & Francis Group: New York, NY, 2017.
[http://dx.doi.org/10.1201/9781315111896]
[11]
Jayanthi, B.; Manna, P.K.; Madhusudhan, S.; Mohanta, G.P.; Manavalan, R. Per oral extended-release products-an overview. J. Appl. Pharm. Sci., 2011, 1(2), 50-55.
[12]
Christianson, E. Advantages and disadvantages of extended-release products., www.meded101.com/ extended-release products (Accessed October 25, 2019).
[13]
Sansom, L.N. Oral extended-release products. Aust. Prescr., 1999, 22(4), 1-7.
[http://dx.doi.org/10.18773/austprescr.1999.072]
[14]
Shargel, L.; Wu-Pong, S.; Yu, A. Applied Biopharmaceutics and Pharmacokinetics, 6th ed; Appleton & Lange Reviews/McGraw-Hill: New York, NY, 2005.
[15]
Guidance for industry: Extended-release oral dosage forms: development,evaluation, and application of in-vitro/in-vivo correlations. www.fda.gov/cder/guidance/index.html (Accessed October 27, 2019)
[16]
Abrams, P. Describing bladder storage function: overactive bladder syndrome and detrusor overactivity. Urology, 2003, 62(5)(Suppl. 2), 28-37.
[http://dx.doi.org/10.1016/j.urology.2003.09.050] [PMID: 14662404]
[17]
Wein, A.J. Pharmacological agents for the treatment of urinary incontinence due to overactive bladder. Expert Opin. Investig. Drugs, 2001, 10(1), 65-83.
[http://dx.doi.org/10.1517/13543784.10.1.65] [PMID: 11116281]
[18]
Andersson, K.E. On the site and mechanism of action of β3-adrenoceptor agonists in the bladder. Int. Neurourol. J., 2017, 21(1), 6-11.
[http://dx.doi.org/10.5213/inj.1734850.425] [PMID: 28361520]
[19]
Eltink, C.; Lee, J.; Schaddelee, M.; Zhang, W.; Kerbusch, V.; Meijer, J.; van Marle, S.; Grunenberg, N.; Kowalski, D.; Drogendijk, T.; Moy, S.; Iitsuka, H.; van Gelderen, M.; Matsushima, H.; Sawamoto, T. Single dose pharmacokinetics and absolute bioavailability of mirabegron, a β3-adrenoceptor agonist for treatment of overactive bladder. Int. J. Clin. Pharmacol. Ther., 2012, 50(11), 838-850.
[http://dx.doi.org/10.5414/CP201782] [PMID: 22943933]
[20]
Krauwinkel, W.; van Dijk, J.; Schaddelee, M.; Eltink, C.; Meijer, J.; Strabach, G.; van Marle, S.; Kerbusch, V.; van Gelderen, M. Pharmacokinetic properties of mirabegron, a β3-adrenoceptor agonist: results from two phase I, randomized, multiple-dose studies in healthy young and elderly men and women. Clin. Ther., 2012, 34(10), 2144-2160.
[http://dx.doi.org/10.1016/j.clinthera.2012.09.010] [PMID: 23063375]
[21]
Iitsuka, H.; Tokuno, T.; Amada, Y.; Matsushima, H.; Katashima, M.; Sawamoto, T.; Takusagawa, S.; van Gelderen, M.; Tanaka, T.; Miyahara, H. Pharmacokinetics of mirabegron, a β3-adrenoceptor agonist for treatment of overactive bladder, in healthy Japanese male subjects: results from single- and multiple-dose studies. Clin. Drug Investig., 2014, 34(1), 27-35.
[http://dx.doi.org/10.1007/s40261-013-0146-1] [PMID: 24178236]
[22]
Takusagawa, S.; van Lier, J.J.; Suzuki, K.; Nagata, M.; Meijer, J.; Krauwinkel, W.; Schaddelee, M.; Sekiguchi, M.; Miyashita, A.; Iwatsubo, T.; van Gelderen, M.; Usui, T. Absorption, metabolism and excretion of [(14)C]mirabegron (YM178), a potent and selective β(3)-adrenoceptor agonist, after oral administration to healthy male volunteers. Drug Metab. Dispos., 2012, 40(4), 815-824.
[http://dx.doi.org/10.1124/dmd.111.043588] [PMID: 22269146]
[23]
Takasu, T.; Sato, S.; Ukai, M.; Maruyama, T.; Shibasaki, M. Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient. U.S. Patent RE44, 872, 2014, April 29 2014.
[24]
Takaishi, Y.; Nakamura, S.; Takahashi, Y. Pharmaceutical composition for modified release. U.S. Patent 0,126,565, May 7 2015.
[25]
Robinson, D.; Thiagamoorthy, G.; Cardozo, L. A drug safety evaluation of mirabegron in the management of overactive bladder. Expert Opin. Drug Saf., 2016, 15(5), 689-696.
[http://dx.doi.org/10.1517/14740338.2016.1165663] [PMID: 26980445]
[26]
Australian public assessment report for mirabegron. 2014.https://www.google.com/auspar-mirabegron-140109%20(Accessed November 14 2019)
[27]
European Medicines Agency, 2012.https://www.EMA/706651/2012/corr (Accessed 14 Nov 2019)
[28]
Suzuki, M.; Ukai, M.; Ohtake, A. Pharmaceutical composition for treating overactive bladder. U.S. Patent 8,772,315, July 8 2014.
[29]
Takaishi, Y.; Nakamura, S. Pharmaceutical composition for modified release. U.S. Patent 8,877,214, November 4 2014.
[30]
Takae, S.; Sakai, T.; Kasashima, Y.; Ansei, Y.; Kiyota, T. Pharmaceutical composition containing mirabegron. U.S. Patent 10,058,536,August 28 2018.
[31]
Kasashima, Y.; Yoshihara, K.; Ito, Y.; Yoshida, T.; Matsul, Y. Pharmaceutical composition containing mirabegron. U.S Patent 0,031,734 January 29, 2015.
[32]
Takahashi, Y.; Nishizato, T.; Murayama, D.; Murayama, E.; Nakamura, S.; Sako, K. Pharmaceutical composition for modified release.U.S. Patent 0,231,965, August 17, 2017.
[33]
Takahashi, Y.; Nishizato, T.; Murayama, D.; Murayama, E.; Nakamura, S.; Sako, K. Pharmaceutical composition for modified release.U.S. Patent 0,231,965, April 16 2018.
[34]
Ishii, T.; Kondo, H.; Yoshihara, K.; Namiki, S. Mirabegron containing release control tablet., Japan Patent 201618818, 2016 April;11
[35]
Tsutsui, Y.; Takayasu, T.; Masashi, H. Pharmaceutical composition for oral administration., WIPO Patent 2015129893, September 3,. 2015.
[36]
Huang, C-M.; Chuang, L-C.; Li, C-H. Sustained-release pharmaceutical composition and preparation method thereof. U.S. Patent 20160354328,, 2016 December;8
[37]
Yanaji, T.; Nozawa, K.; Umemura, K.; Arimura, K.; Takada, M. Mirabegron-containing tablet, method for producing mirabegroncontaining pharmaceutical preparation, and method for producing mirabegron-containing granulated product. U.S. Patent 20180185339,July 5 2018.
[38]
Sako, K.; Sawada, T.; Yoshihara, K.; Yoshioka, T.; Watanabe, S. Stable pharmaceutical composition for oral use. U.S. Patent 6,562,375,May 13 2003.
[39]
Beijing Rundekang Pharmaceutical Technology Co. Ltd. Merariveron sustained-release tablet and preparation method thereof. Chinese Patent103655503, March 26 2014.
[40]
Longxia, L.; Juan, S.; Gang, D.; Yuwei, J.; Xiaoking, Z.; Dadan, H. Mirabegron sustained-release tablet composition., Chinese Patent 103655503, March 26. 2014.
[41]
Beijing Boze Derun Pharmaceutical Technology Development Co.Ltd.. Tablet composition with solubilizing and slow-release effects.Chinese Patent 104288117, January 21 2015.
[42]
Jinzhi, S.; Lingyu, Y.; Dongxia, J. Mirabegron composition., Chinese Patent 106361715, February 1. 2017.
[43]
Yang, B.L.; Tieqiang, H.H. Mirabegron composition., Chinese Patent 106361715, February 1, . 2017.
[44]
Depei, G.; Qihua, W. Mirabegron sustained-release tablet and preparation method thereof., Chinese Patent 104352475,, 2015 February;18
[45]
Chenxi, T.; Jiangtao, B.; Hailong, Z.; Wei, L.; Bo, C. Mira release pharmaceutical composition veron., Chinese Patent 104523635, May 3,. 2017.
[46]
Jie, Y.; Xuan, L. Mirabegron medicine composition and preparation method thereof., Chinese Patent 105641706, June 8, . 2016.
[47]
Xiaoming, Q.; Xeujun, L. Lisheng, C. Mirabegron sustained-release tablet and preparation method thereof. Chinese Patent 105769786,2016 July;20
[48]
Xiaoming, Q.; Xeujun, L.; Lisheng, C.; Yongtao, M.; Feng, L.; Xing, X.; Yanjun, Y.W. Mirabegron sustained-release tablet and preparation method thereof., Chinese Patent 107397733, November 28. 2016.
[49]
Chapple, C.R.; Amarenco, G.; López Aramburu, M.A.; Everaert, K.; Liehne, J.; Lucas, M.; Vik, V.; Ridder, A.; Snijder, R.; Yamaguchi, O. BLOSSOM Investigator Group. A proof-of-concept study: mirabegron, a new therapy for overactive bladder. Neurourol. Urodyn., 2013, 32(8), 1116-1122.
[http://dx.doi.org/10.1002/nau.22373] [PMID: 23424164]
[50]
Thiagamoorthy, G.; Kotes, S.; Zacchè, M.; Cardozo, L. The efficacy and tolerability of mirabegron, a β3 adrenoceptor agonist, in patients with symptoms of overactive bladder. Ther. Adv. Urol., 2016, 8(1), 38-46.
[http://dx.doi.org/10.1177/1756287215614237] [PMID: 26834839]
[51]
Nitti, V.W.; Auerbach, S.; Martin, N.; Calhoun, A.; Lee, M.; Herschorn, S. Results of a randomized phase III trial of mirabegron in patients with overactive bladder. J. Urol., 2013, 189(4), 1388-1395.
[http://dx.doi.org/10.1016/j.juro.2012.10.017] [PMID: 23079373]
[52]
Herschorn, S.; Barkin, J.; Castro-Diaz, D.; Frankel, J.M.; Espuna-Pons, M.; Gousse, A.E.; Stölzel, M.; Martin, N.; Gunther, A.; Van Kerrebroeck, P. A phase III, randomized, double-blind, parallel-group, placebo-controlled, multicentre study to assess the efficacy and safety of the β3 adrenoceptor agonist, mirabegron, in patients with symptoms of overactive bladder. Urology, 2013, 82(2), 313-320.
[http://dx.doi.org/10.1016/j.urology.2013.02.077] [PMID: 23769122]
[53]
Yamaguchi, O.; Kakizaki, H.; Homma, Y.; Igawa, Y.; Takeda, M.; Nishizawa, O.; Gotoh, M.; Yoshida, M.; Yokoyama, O.; Seki, N.; Okitsu, A.; Hamada, T.; Kobayashi, A.; Kuroishi, K. Safety and efficacy of mirabegron as ‘add-on’ therapy in patients with overactive bladder treated with solifenacin: a post-marketing, open-label study in Japan (MILAI study). BJU Int., 2015, 116(4), 612-622.
[http://dx.doi.org/10.1111/bju.13068] [PMID: 25639296]
[54]
Abrams, P.; Kelleher, C.; Staskin, D.; Rechberger, T.; Kay, R.; Martina, R.; Newgreen, D.; Paireddy, A.; van Maanen, R.; Ridder, A. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony). Eur. Urol., 2015, 67(3), 577-588.
[http://dx.doi.org/10.1016/j.eururo.2014.02.012] [PMID: 24612659]
[55]
Drake, M.J.; Chapple, C.; Esen, A.A.; Athanasiou, S.; Cambronero, J.; Mitcheson, D.; Herschorn, S.; Saleem, T.; Huang, M.; Siddiqui, E.; Stölzel, M.; Herholdt, C.; MacDiarmid, S. Efficacy and safety of mirabegron add-on therapy to solifenacin in incontinent overactive bladder patients with an inadequate response to initial 4-week solifenacin monotherapy: a randomised double-blind multicentre phase 3b study (BESIDE). Eur. Urol., 2016, 70(1), 136-145.
[56]
Dehvari, N.; da Silva Junior, E.D.; Bengtsson, T.; Hutchinson, D.S. Mirabegron: potential off target effects and uses beyond the bladder. Br. J. Pharmacol., 2018, 175(21), 4072-4082.
[http://dx.doi.org/10.1111/bph.14121] [PMID: 29243229]
[57]
Mo, W.; Michel, M.C.; Lee, X.W.; Kaumann, A.J.; Molenaar, P. The β3 -adrenoceptor agonist mirabegron increases human atrial force through β1 -adrenoceptors: an indirect mechanism? Br. J. Pharmacol., 2017, 174(16), 2706-2715.
[http://dx.doi.org/10.1111/bph.13897] [PMID: 28574581]
[58]
van Gelderen, M.; Stölzel, M.; Meijer, J.; Kerbusch, V.; Collins, C.; Korstanje, C. An exploratory study in healthy male subjects of the mechanism of mirabegron-induced cardiovascular effects. J. Clin. Pharmacol., 2017, 57(12), 1534-1544.
[http://dx.doi.org/10.1002/jcph.952] [PMID: 28618007]
[59]
Alexandre, E.C.; Kiguti, L.R.; Calmasini, F.B.; Silva, F.H.; da Silva, K.P.; Ferreira, R.; Ribeiro, C.A.; Mónica, F.Z.; Pupo, A.S.; Antunes, E. Mirabegron relaxes urethral smooth muscle by a dual mechanism involving β3 -adrenoceptor activation and α1 -adrenoceptor blockade. Br. J. Pharmacol., 2016, 173(3), 415-428.
[http://dx.doi.org/10.1111/bph.13367] [PMID: 26493129]
[60]
Takusagawa, S.; Miyashita, A.; Iwatsubo, T.; Usui, T. In vitro inhibition and induction of human cytochrome P450 enzymes by mirabegron, a potent and selective β3-adrenoceptor agonist. Xenobiotica, 2012, 42(12), 1187-1196.
[http://dx.doi.org/10.3109/00498254.2012.700140] [PMID: 22834478]
[61]
Takusagawa, S.; Yajima, K.; Miyashita, A.; Uehara, S.; Iwatsubo, T.; Usui, T. Identification of human cytochrome P450 isoforms and esterases involved in the metabolism of mirabegron, a potent and selective β3-adrenoceptor agonist. Xenobiotica, 2012, 42(10), 957-967.
[http://dx.doi.org/10.3109/00498254.2012.675095] [PMID: 22509825]
[62]
Batista, J.E.; Kölbl, H.; Herschorn, S.; Rechberger, T.; Cambronero, J.; Halaska, M.; Coppell, A.; Kaper, M.; Huang, M.; Siddiqui, E. BEYOND study group.The efficacy and safety of mirabegron compared with solifenacin in overactive bladder patients dissatisfied with previous antimuscarinic treatment due to lack of efficacy: results of a noninferiority, randomized, phase IIIb trial. Ther. Adv. Urol., 2015, 7(4), 167-179.
[http://dx.doi.org/10.1177/1756287215589250] [PMID: 26445596]
[63]
Kaplan, S.A.; Herschorn, S.; McVary, K.T.; Staskin, D.; Chapple, C.; Foley, S.; Cambronero Santos, J.; Kristy, R.M.; Choudhury, N.; Hairston, J.; Schermer, C.R. Efficacy and safety of mirabegron versus placebo add-on therapy in men with overactive bladder symptoms receiving tamsulosin for underlying benign prostatic hyperplasia: A randomized, Phase 4 study (PLUS). J. Urol., 2020, 203(6), 1163-1171.
[64]
Rey, A.W.; Bhattacharyya, A.; Gerster, J.L.; Duncan, S.C.; Raheem, M.A.; Wang, F.; Green, S.P. Solid forms of mirabegron. U.S. Patent 20170291882, Oct 12 2017.
[65]
Peddy, V.; Boge, R. Amorphous mirabegron and processes for crystal forms of mirabegron. U.S. Patent 9,283,210, Mar 15 2016.
[66]
Peddy, V.; Boge, R.; Gatani, Y.S.; Shinde, N.; Ghosh, P.K.; Seetharaman, S.; Vaya, N.; Sihorkar, V.; Totad, R.; Venkatesh, A.; Katkar, G.A.; Mova, S.; Chudiwal, P. Amorphous mirabegron and processes for crystal forms of mirabegron. U.S. Patent 9,655,885, May 23 2017.


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 21
ISSUE: 2
Year: 2020
Page: [79 - 88]
Pages: 10
DOI: 10.2174/1389200221666200425211139
Price: $65

Article Metrics

PDF: 33
HTML: 6
EPUB: 1